Synergistic effects of Artemisia iwayomogi and Curcuma longa radix on high-fat diet-induced hyperlipidemia in a mouse model

Journal of Ethnopharmacology

Volumn 173, Issue , 2015, Pages 217-224

  Han, Jong Min ^a   Lee, Jin Seok ^a   Kim, Hyeong Geug ^a   Seol, In Chan ^a   Im, Hwi Jin ^a   Cho, Jung Hyo ^a   Son, Chang Gue ^a  

^a Daejeon University   (South Korea)

Author keywords

Artemisia iwayomogi; Curcuma longa radix; Hyperlipidemia; Synergistic effect; Traditional Korean medicine

Indexed keywords

ANTILIPEMIC AGENT; ARTEMISIA IWAYOMOGI EXTRACT; CATALASE; CURCUMA LONGA RADIX EXTRACT; FATTY ACID SYNTHASE; GLUCOSE; GLUTATHIONE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PLANT EXTRACT; STEROL REGULATORY ELEMENT BINDING PROTEIN 1C; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; CHOLESTEROL;

ADIPOCYTE; ADIPOSE TISSUE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTEMISIA; ARTEMISIA IWAYOMOGI; ARTICLE; BODY WEIGHT; CHOLESTEROL LIVER LEVEL; CONTROLLED STUDY; CURCUMA LONGA; CURCUMA LONGA RADIX; DRUG POTENTIATION; ENZYME ACTIVITY; FATTY LIVER; FOOD INTAKE; GENE EXPRESSION; HISTOPATHOLOGY; HYPERLIPIDEMIA; INTRAABDOMINAL FAT; LIPID BLOOD LEVEL; LIPID DIET; LIPID LIVER LEVEL; LIPID STORAGE; LIPOGENESIS; LIVER WEIGHT; MALE; MOUSE; NONHUMAN; OBESITY; OXIDATIVE STRESS; ANIMAL; BLOOD; C57BL MOUSE; CHINESE MEDICINE; CURCUMA; DISEASE MODEL; DRUG EFFECTS; HYPERLIPIDEMIAS; KOREAN MEDICINE; LIVER; METABOLISM; PHYTOTHERAPY;

ARTEMISIA IWAYOMOGI; CURCUMA LONGA; MUS;

ADIPOSE TISSUE; ANIMALS; ARTEMISIA; CHOLESTEROL; CURCUMA; DIET, HIGH-FAT; DISEASE MODELS, ANIMAL; DRUG SYNERGISM; GENE EXPRESSION; HYPERLIPIDEMIAS; HYPOLIPIDEMIC AGENTS; LIVER; MALE; MEDICINE, CHINESE TRADITIONAL; MEDICINE, KOREAN TRADITIONAL; MICE, INBRED C57BL; PHYTOTHERAPY; PLANT EXTRACTS; TRIGLYCERIDES;

EID: 84938508253     PISSN: 03788741     EISSN: 18727573     Source Type: Journal    
DOI: 10.1016/j.jep.2015.07.021     Document Type: Article

References (37)

1. Australian Bureau of Statistics, 2012. Australian Healt h Survey: Biomedical Results for Chronic Diseases, 2011-2012
2. Drugs.com. 2015. Antihyperlipidemic agents. (accessed 03.02.15.).
3. M. den Boer, P.J. Voshol, F. Kuipers, L.M. Havekes, and J.A. Romijn Hepatic steatosis: a mediator of the metabolic syndrome. Lessons from animal models Arterioscler. Thromb. Vasc. Biol. 24 2004 644 649 10.1161/01.ATV.0000116217.57583.6e
4. T.P. Carr, C.J. Andresen, and L.L. Rudel Enzymatic determination of triglyceride, free cholesterol, and total cholesterol in tissue lipid extracts Clin. Biochem. 26 1993 39 42 10.1016/0009-9120(93)90015-X
5. G. Chinetti, J.-C. Fruchart, and B. Staels Peroxisome proliferator-activated receptors (PPARs): nuclear receptors at the crossroads between lipid metabolism and inflammation Inflamm. Res. 49 2000 497 505 10.1007/s000110050622
6. Y. Choi, Y. Yanagawa, S. Kim, W.K. Whang, and T. Park Artemisia iwayomogi extract attenuates high-fat diet-induced obesity by decreasing the expression of genes associated with adipogenesis in mice Evid. Based Complement. Altern. Med. 2013 2013 e915953 10.1155/2013/915953
7. Cholesterol Treatment Trialists' (CTT) Collaboration Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials Lancet 376 2010 1670 1681 10.1016/S0140-6736(10)61350-5
8. P. Durrington Dyslipidaemia Lancet 362 2003 717 731
9. G.L. Ellman Tissue sulfhydryl groups Arch Biochem Biophys 82 1959 70 77
10. S.D. de Ferranti Drug therapy for hypercholesterolemia and dyslipidemia Ricardo Munoz, Carol G. Schmitt, Stephen J. Roth, Eduardo da Cruz, Handbook of Pediatric Cardiovascular Drugs 2008 Springer London 318 333
11. S. Furukawa, T. Fujita, M. Shimabukuro, M. Iwaki, Y. Yamada, Y. Nakajima, O. Nakayama, M. Makishima, M. Matsuda, and I. Shimomura Increased oxidative stress in obesity and its impact on metabolic syndrome J. Clin. Invest. 114 2004 1752 1761 10.1172/JCI21625
12. M.A. Giorgi, C. Caroli, H.C. Arazi, and G. Di Girolamo Pharmacogenomics and adverse drug reactions: the case of statins Expert Opin. Pharmacother. 12 2011 1499 1509 10.1517/14656566.2011.563734
13. J.-M. Han, H.-G. Kim, M.-K. Choi, J.-S. Lee, H.-J. Park, J.-H. Wang, J.-S. Lee, S.-W. Son, S.-Y. Hwang, and C.-G. Son Aqueous extract of Artemisia iwayomogi Kitamura attenuates cholestatic liver fibrosis in a rat model of bile duct ligation Food Chem. Toxicol. 50 2012 3505 3513 10.1016/j.fct.2012.07.018
14. I. Hayashi, Y. Morishita, K. Imai, M. Nakamura, K. Nakachi, and T. Hayashi High-throughput spectrophotometric assay of reactive oxygen species in serum Mutat. Res. 631 2007 55 61 10.1016/j.mrgentox.2007.04.006
15. E. Hopps, D. Noto, G. Caimi, and M.R. Averna A novel component of the metabolic syndrome: the oxidative stress Nutr. Metab. Cardiovasc. Dis. 20 2010 72 77
16. E.-M. Jang, M.-S. Choi, U.J. Jung, M.-J. Kim, H.-J. Kim, S.-M. Jeon, S.-K. Shin, C.-N. Seong, and M.-K. Lee Beneficial effects of curcumin on hyperlipidemia and insulin resistance in high-fat-fed hamsters Metabolism 57 2008 1576 1583 10.1016/j.metabol.2008.06.014
17. M.D. Jensen, D.H. Ryan, C.M. Apovian, J.D. Ard, A.G. Comuzzie, K.A. Donato, F.B. Hu, V.S. Hubbard, J.M. Jakicic, R.F. Kushner, C.M. Loria, B.E. Millen, C.A. Nonas, F.X. Pi-Sunyer, J. Stevens, V.J. Stevens, T.A. Wadden, B.M. Wolfe, and S.Z. Yanovski 2013 AHA/ACC/TOS Guideline for the Management of Overweight and Obesity in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and The Obesity Society Circulation 129 2014 S102 S138 10.1161/01.cir.0000437739.71477.ee
18. T.P. Johnston, J.C. Baker, D. Hall, S. Jamal, W.K. Palmer, and E.E. Emeson Regression of poloxamer 407-induced atherosclerotic lesions in C57BL/6 mice using atorvastatin Atherosclerosis 149 2000 303 313 10.1016/S0021-9150(99)00339-1
19. A.-A.M. Kamal, A. Gomaa, M.E. Khafif, and A.S. Hammad Plasma lipid peroxides among workers exposed to silica or asbestos dusts Environ. Res. 49 1989 173 180 10.1016/S0013-9351(89)80062-3
20. Y. Kambayashi, N.T. Binh, H.W. Asakura, Y. Hibino, Y. Hitomi, H. Nakamura, and K. Ogino Efficient assay for total antioxidant capacity in human plasma using a 96-well microplate J. Clin. Biochem. Nutr. 44 2009 46 51 10.3164/jcbn.08-162
21. J.F. Keaney, M.G. Larson, R.S. Vasan, P.W. Wilson, I. Lipinska, D. Corey, J.M. Massaro, P. Sutherland, J.A. Vita, and E.J. Benjamin Obesity and systemic oxidative stress clinical correlates of oxidative stress in the Framingham Study Arterioscler. Thromb. Vasc. Biol. 23 2003 434 439
22. H.-J. Kim, M. Miyazaki, W.C. Man, and J.M. Ntambi Sterol regulatory element-binding proteins (SREBPs) as regulators of lipid metabolism Ann. NY Acad. Sci. 967 2002 34 42 10.1111/j.1749-6632.2002.tb04261.x
23. A.J. Krentz From "Bad Pharma" to better guidance? Cardiovasc. Endocrinol. 2 2013 1 3 10.1097/XCE.0b013e32835fdee7
24. Kuklina E.V., (US), N.C. for H.S., others, 2013. Trends in high LDL cholesterol, cholesterol-lowering medication use, and dietary saturated-fat intake: United States, 1976-2010. US Department of Health and Human Services, Centers for Disease Control and Prevention, National Center for Health Statistics
25. J.-M. Li, Y.-C. Li, L.-D. Kong, and Q.-H. Hu Curcumin inhibits hepatic protein-tyrosine phosphatase 1B and prevents hypertriglyceridemia and hepatic steatosis in fructose-fed rats Hepatology 51 2010 1555 1566 10.1002/hep.23524
26. S. Magder Reactive oxygen species: toxic molecules or spark of life Crit. Care 10 2006 208
27. M.S.D. Maggo, M.A. Kennedy, and D.W. Clark Clinical implications of pharmacogenetic variation on the effects of statins Drug Saf. 34 2011 1 19
28. S. Mandard, M. Müller, and S. Kersten Peroxisome proliferator-activated receptor α target genes Cell. Mol. Life Sci. CMLS 61 2004 393 416 10.1007/s00018-003-3216-3
29. H. Manjunatha, and K. Srinivasan Hypolipidemic and antioxidant effects of dietary curcumin and capsaicin in induced hypercholesterolemic rats Lipids 42 2007 1133 1142 10.1007/s11745-007-3120-y
30. D. Preiss, and N. Sattar Non-alcoholic fatty liver disease: an overview of prevalence, diagnosis, pathogenesis and treatment considerations Clin. Sci. 115 2008 141 10.1042/CS20070402
31. E. Ravussin, S. Lillioja, W.C. Knowler, L. Christin, D. Freymond, W.G. Abbott, V. Boyce, B.V. Howard, and C. Bogardus Reduced rate of energy expenditure as a risk factor for body-weight gain N. Engl. J. Med. 318 1988 467 472
32. H.-S. Shin, J.-M. Han, H.-G. Kim, M.-K. Choi, C.-G. Son, H.-R. Yoo, H.-K. Jo, and I.-C. Seol Anti-atherosclerosis and hyperlipidemia effects of herbal mixture, Artemisia iwayomogi Kitamura and Curcuma longa Linne, in apolipoprotein E-deficient mice J. Ethnopharmacol. 153 2014 142 150 10.1016/j.jep.2014.01.039
33. D.P.P. Toth Drug treatment of hyperlipidaemia Drugs 70 2010 1363 1379 10.2165/10898610-000000000-00000
34. P.P. Toth, T.D. Dayspring, and G.S. Pokrywka Drug therapy for hypertriglyceridemia: fibrates and omega-3 fatty acids Curr. Atheroscler. Rep. 11 2008 71 79 10.1007/s11883-009-0012-z
35. C.R. Wheeler, J.A. Salzman, N.M. Elsayed, S.T. Omaye, and D.W. Korte Jr. Automated assays for superoxide dismutase, catalase, glutathione peroxidase, and glutathione reductase activity Anal. Biochem. 184 1990 193 199
36. W. Xie, Y. Zhao, and L. Du Emerging approaches of traditional Chinese medicine formulas for the treatment of hyperlipidemia J. Ethnopharmacol. 140 2012 345 367 10.1016/j.jep.2012.01.027
37. W.-F. Yiu, P.-L. Kwan, C.-Y. Wong, T.-S. Kam, S.-M. Chiu, S.-W. Chan, and R. Chan Attenuation of fatty liver and prevention of hypercholesterolemia by extract of Curcuma longa through regulating the expression of CYP7A1, LDL-receptor, HO-1, and HMG-CoA reductase J. Food Sci. 76 2011 H80 H89 10.1111/j.1750-3841.2011.02042.x